Topic: venture capital (VC)
Third Rock Ventures has named Steven Kafka, former president and chief operating officer of Foundation Medicine, as a new venture partner.
The series C continues a transformative year defined by the acquisition of GSK's portfolio of approved and experimental rare disease gene therapies.
MD Anderson and Accelerator Life Science Partners unveiled Magnolia Neurosciences, to develop neuroprotective drugs with a $31 million series A.
The series B round sees more big-name investors give cash to researchers whose earlier work on PARP inhibitor Lynparza put DDR on the map.
The Novo Holdings-led mezzanine round comes six months after Therachon began testing its FGFR3 ligand trap in healthy volunteers.
The series C sets the Roche-partnered MIT spinout to advance cell therapy treatments of solid tumors and autoimmune diseases toward the clinic.
Ambys Medicines will develop cell and gene therapies, as well as drugs, for chronic liver diseases.
The Boston-based biotech unveiled the series A round alongside the appointment of a Spark Therapeutics co-founder and other organizational changes.
The series B round comes six months after ReViral completed a phase 2a evaluation of RSV fusion inhibitor RV521 in healthy volunteers.
Inversago Pharma reeled in $7 million to move a suite of next-generation cannabinoid receptor-1 blockers into the clinic.